Iñaki Sanz
Emory University, Department of Medicine, Division of Rheumatology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Iñaki Sanz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03949855 · Belimumab With Rituximab for Primary Membranous NephropathyNational Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Membranous Nephropathy, Nephrotic Syndrome · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:24 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.Arthritis Rheum · 2004635 citationsRCR 13.8
- Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.Arthritis Rheum · 2004366 citationsRCR 7.3
- The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.Arthritis Rheum · 2003359 citationsRCR 7.6
- Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.Arthritis Rheum · 2010189 citationsRCR 4.4
- 132 citationsRCR 2.7
- Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.Arthritis Rheumatol · 201880 citationsRCR 3.2
- Effect of systemic antibiotics on clinical and patient-reported outcomes of implant therapy - a multicenter randomized controlled clinical trial.Clin Oral Implants Res · 201452 citationsRCR 3.1
- The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis.J Transl Med · 201549 citationsRCR 1.8
- Randomized trial of omega-3 for autism spectrum disorders: Effect on cell membrane composition and behavior.Eur Neuropsychopharmacol · 201745 citationsRCR 2.3
- Clinical study comparing the efficacy of two denture adhesives in complete denture patients.Int J Prosthodont · 200936 citationsRCR 2.2